中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.01 seconds)

    PHARMACEUTICAL COMBINATIONS
    1.
    发明申请
    PHARMACEUTICAL COMBINATIONS 有权

    公开(公告)号：US20210363254A1

    公开(公告)日：2021-11-25

    申请号：US16981828

    申请日：2019-03-18

    Applicant: Novartis AG

    Inventor： Stephane FERRETTI ,  Nelson GUERREIRO ,  Ensar HALILOVIC ,  Sebastien JEAY ,  Astrid JULLION ,  Jinsheng LIANG ,  Christophe MEILLE ,  Hui-Qin WANG ,  Jens WUERTHNER

    IPC: C07K16/28 ,  A61P35/00 ,  C07D487/04

    Abstract: The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) a HDM2-p53 interaction inhibitor, said combination for simultaneous, separate or sequential administration for use in the treatment of a proliferative disease, a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination; said proliferative disease being a TP53 wildtype tumor, in particular TP53 wildtype renal cell carcinoma (RCC) or TP53 wildtype colorectal cancer (CRC).

    DOSING REGIMEN FOR TREATING A DISEASE MODULATED BY CSF-1R
    3.
    发明公开
    DOSING REGIMEN FOR TREATING A DISEASE MODULATED BY CSF-1R 审中-公开

    公开(公告)号：US20230172920A1

    公开(公告)日：2023-06-08

    申请号：US17996616

    申请日：2021-04-19

    Applicant: Novartis AG

    Inventor： Astrid JULLION ,  Christophe MEILLE ,  Cornelia QUADT ,  Michael John ROY ,  Marion WIESMANN

    IPC: A61K31/4439 ,  A61P25/28

    CPC classification number: A61K31/4439 ,  A61P25/28

    Abstract: The present disclosure relates to the field of pharmacy, particularly to a CSF-1R inhibitor for use in the treatment of disease modulated by CSF-1R. For example, the disclosure relates to a CSF-1R inhibitor for use in the treatment of cancer or neurodegenerative diseases. The disclosure also relates to a CSF-1R inhibitor or a pharmaceutical combination comprising a CSF-1R inhibitor, or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody molecule, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer; to a method for the treatment of cancer that involves administering a CSF-1R inhibitor or the combination; and to the use of a CSF-1R inhibitor or the combination for the manufacture of a medicament for the treatment of cancer.

    PHARMACEUTICAL COMBINATIONS
    5.
    发明申请
    PHARMACEUTICAL COMBINATIONS 有权

    公开(公告)号：US20210386763A1

    公开(公告)日：2021-12-16

    申请号：US17415985

    申请日：2019-12-18

    Applicant: NOVARTIS AG

    Inventor： Nelson GUERREIRO ,  Ensar HALILOVIC ,  Astrid JULLION ,  Christophe MEILLE ,  Youzhen WANG

    IPC: A61K31/635 ,  A61K31/506 ,  A61K45/06 ,  A61P35/02

    Abstract: The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax]. The present invention further relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment.

Patent Agency Ranking